CDx tools provider Janssen Pharmaceuticals has entered a partnership with Predicine to develop a urine-based test as a CDx tool to identify bladder cancer patients who may find targeted therapies effective. Financial terms of the partnership were not disclosed.
California-based Predicine’s next-generation sequencing-based (NGS) test is used to detect cell-free DNA alterations to cancer-relevant genes, including single nucleotide variants, insertions, deletions, fusions, and copy number variations.
In August 2022, Predicine also secured a CE-IVD mark for PredicineCare as a blood and urine cfDNA test that is capable of targeting 152 genes which are actionable and linked with available therapies or those in clinical trials. In addition, in August 2022, the company received the US FDA breakthrough device designation for the PredicineCare test.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.